Overview
HRTX market data
Price History
HRTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.12 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.67 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.38 – $1.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $86.9 · P/B 16.63 · P/S 0.58.
Company news
8-K filing — HERON THERAPEUTICS, INC. /DE/ (HRTX)SEC EDGAR · Jun 25, 2026, 9:00 PM
Heron Therapeutics shares are trading lower after Delaware court invalidated key CINVANTI patent claims in litigation with Azurity.Benzinga · Jun 2, 2026, 2:19 PM
Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With AzurityBenzinga · Jun 2, 2026, 12:21 PM
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.Benzinga · May 11, 2026, 12:56 PM
Heron Therapeutics Affirms FY2026 Sales Guidance of $173.000M-$183.000M vs $174.733M EstBenzinga · May 11, 2026, 12:02 PM
Heron Therapeutics Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $34.711M Miss $38.350M EstimateBenzinga · May 11, 2026, 12:01 PM
Earnings Scheduled For May 11, 2026Benzinga · May 11, 2026, 11:11 AM